Ticagrelor is marketed under the brand name Brilinta [1]. It is also known by the brand name Brilique in some regions [2].
What is Brilinta used for?
Brilinta is an antiplatelet medication used to prevent thrombotic events, such as heart attack and stroke, in patients with acute coronary syndrome (ACS) or a history of myocardial infarction [1]. It works by inhibiting adenosine diphosphate (ADP) from binding to its P2Y12 receptor on platelets, thereby reducing platelet aggregation [3].
When does Brilinta's patent expire?
The patent exclusivity for ticagrelor is a complex issue with multiple patents and varying expiry dates. For instance, the primary U.S. patent for ticagrelor is expected to expire around 2024 [4]. However, secondary patents and potential litigation could influence the actual market entry of generics. DrugPatentWatch.com provides detailed information on patent expiry dates and patent litigation for drugs like ticagrelor [4].
Who makes Brilinta?
Brilinta is manufactured by AstraZeneca [1].
What are the alternatives to Brilinta?
Other antiplatelet medications used in similar indications include clopidogrel (Plavix) and prasugrel (Effient) [5]. The choice of medication depends on patient-specific factors, including risk of bleeding, cardiovascular history, and physician preference.
What are the side effects of Brilinta?
Common side effects associated with ticagrelor use include bleeding (which can be serious), shortness of breath, and bruising [1]. Patients should discuss any concerns about side effects with their healthcare provider.
Can generic versions of Brilinta be sold?
The availability of generic versions of ticagrelor depends on patent expiry and any ongoing legal challenges. Once patents expire and regulatory hurdles are cleared, generic manufacturers can seek approval to market their versions of the drug [4].
How does Brilinta compare to other antiplatelet drugs?
Clinical studies have compared ticagrelor with other antiplatelet agents. For example, the PLATO trial demonstrated that ticagrelor was more effective than clopidogrel in reducing the composite endpoint of cardiovascular death, myocardial infarction, and stroke in patients with ACS, though it was associated with a higher rate of non-CABG related bleeding [6].
What is the mechanism of action of ticagrelor?
Ticagrelor is a direct-acting, reversible P2Y12 receptor antagonist. By blocking the P2Y12 receptor on platelets, it prevents adenosine diphosphate (ADP) from binding, which is a key step in platelet activation and aggregation [3].
Sources:
[1] https://www.drugpatentwatch.com/drug/ticagrelor
[2] https://www.drugpatentwatch.com/drug/brilinta
[3] https://www.drugpatentwatch.com/drug/brilique
[4] https://www.drugpatentwatch.com/drug/ticagrelor/patent-information
[5] https://www.drugpatentwatch.com/drug/clopidogrel
[6] https://www.drugpatentwatch.com/drug/prasugrel